Announcing Pre Orderavailability of Targeted Medical Insights' 2026 US Oncology Benchmark Reports. These reports will benchmark 15+ target Large (e.g. Pfizer, Merck, Eli Lilly, and others!) oncology organzations and 15+ Mid to Small (e.g. Coherus Bioscience, Beigene, Epizyme, and others!) oncology organizations and provide data and insights for all customer facing personnel.
Key Information Topics (KITs) include:
The price for the 2026 United States Oncology Benchmark Report - Large Organizations is $22,500.
The price for the 2026 United States Oncology Benchmark Report - Mid to Small Organizations is $22,500.
Combine both (Over 30 oncology commercial organizations!!) for $40,000.
To learn more including companies included in the report and sample data from previous reports, click the learn more button below!
This study will be available in early March 2026
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.